Abbott Laboratories (ABT) reported $48.23B of revenue for the twelve months ended Sep 30, 2026. That is up 10.0% from the year before. Revenue for fiscal 2025 was $44.33B.

Yes. Abbott Laboratories earned $4.70B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.7%.

How much cash and debt does ABT have?

Abbott Laboratories reported $4.05B in cash and cash equivalents and $31.16B of debt on its most recent balance sheet in SEC filings.

How fast is ABT revenue growing?

Abbott Laboratories's revenue changed +5.7% in fiscal 2025, to $44.33B. Its compound annual growth rate was +5.1% over 5 years and +8.1% over 10 years.

What is ABT gross margin?

Abbott Laboratories's gross profit was $27.46B on $48.23B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 56.9%.

What is ABT free cash flow?

Abbott Laboratories generated $6.76B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $8.86B less capital expenditures.

What is ABT earnings per share?

Diluted earnings per share were $2.68 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did ABT last report financial results?

The latest statements here come from Abbott Laboratories's 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.

Where does this ABT financial data come from?

Quantisnow builds these statements from the structured XBRL data Abbott Laboratories files with the SEC. It is provided for information only and is not investment advice.

Financials · ABT

Abbott Laboratories (ABT) financials

For the twelve months ended Sep 30, 2026, Abbott Laboratories reported $48.23B of revenue and $4.70B of net income.

Revenue, TTM: $48.23B
Revenue growth, YoY: +10.0%
Net income, TTM: $4.70B
Net income growth, YoY: -66.4%
Net margin: 9.7%
Free cash flow, TTM: $6.76B
EPS, diluted, TTM: $2.68
EPS growth, YoY: -66.4%
Cash: $4.05B
Total debt: $31.16B
P/E: 40.50
P/S: 3.95
Market cap: $190.39B

Annual revenue$44.33B

FY2016FY2025

Annual net income$6.52B

FY2016FY2025

Annual free cash flow$7.39B

FY2016FY2025

ABT revenue and earnings growth

ABT revenueQ3 2026$13.01B

Quarter YoY: +14.5%
QoQ: +3.3%
FY YoY: +5.7%
5Y CAGR: +5.1%
10Y CAGR: +8.1%

ABT revenue was $13.01B in fiscal Q3 2026 (ended Sep 30, 2026), up 14.5% from a year earlier and up 3.3% from the prior quarter. For the full fiscal 2025 it was $44.33B, up 5.7% from fiscal 2024. Compound annual growth was +5.1% over 5 years and +8.1% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

ABT net incomeQ3 2026$920.00M

Quarter YoY: -44.0%
QoQ: -0.9%
FY YoY: -51.3%
5Y CAGR: +7.7%
10Y CAGR: +4.0%

ABT net income was $920.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 44.0% from a year earlier and down 0.9% from the prior quarter. For the full fiscal 2025 it was $6.52B, down 51.3% from fiscal 2024. Compound annual growth was +7.7% over 5 years and +4.0% over 10 years. It rose in 5 of the last 10 fiscal years.

ABT EPSQ3 2026$0.53

Quarter YoY: -43.6%
QoQ: +0.0%
FY YoY: -51.3%
5Y CAGR: +8.3%
10Y CAGR: +2.5%

ABT diluted EPS was $0.53 in fiscal Q3 2026 (ended Sep 30, 2026), down 43.6% from a year earlier and up 0.0% from the prior quarter. For the full fiscal 2025 it was $3.72, down 51.3% from fiscal 2024. Compound annual growth was +8.3% over 5 years and +2.5% over 10 years.

ABT free cash flowQ3 2026$1.22B

Quarter YoY: -46.6%
QoQ: -38.5%
FY YoY: +16.4%
5Y CAGR: +5.3%
10Y CAGR: +14.8%

ABT free cash flow was $1.22B in fiscal Q3 2026 (ended Sep 30, 2026), down 46.6% from a year earlier and down 38.5% from the prior quarter. For the full fiscal 2025 it was $7.39B, up 16.4% from fiscal 2024. Compound annual growth was +5.3% over 5 years and +14.8% over 10 years. It rose in 7 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$44.33B	$41.95B	$40.11B	$43.65B	$43.08B	$34.61B	$31.90B	$30.58B	$27.39B	$20.85B
Cost of revenue	$19.32B	$18.71B	$17.98B	$19.14B	$18.54B	$15.00B	$13.23B	$12.71B	$12.41B	$9.09B
Gross profit	$25.01B	$23.24B	$22.13B	$24.51B	$24.54B	$19.61B	$18.67B	$17.87B	$14.98B	$11.76B
Research and development	$2.94B	$2.84B	$2.74B	$2.89B	$2.74B	$2.42B	$2.44B	$2.30B	$2.26B	$1.45B
Selling, general and admin	$12.33B	$11.70B	$10.95B	$11.25B	$11.32B	$9.70B	$9.77B	$9.74B	$9.18B	$6.74B
Operating income	$8.05B	$6.83B	$6.48B	$8.36B	$8.43B	$5.36B	$4.53B	$3.65B	$1.56B	$3.03B
Interest expense	$493.00M	$559.00M	$637.00M	$558.00M	$533.00M	$546.00M	$670.00M	$826.00M	$904.00M	$431.00M
Pre-tax income	$8.47B	$7.01B	$6.66B	$8.31B	$8.21B	$4.97B	$4.08B	$2.87B	$2.23B	$1.41B
Income tax	$1.94B	-$6.39B	$941.00M	$1.37B	$1.14B	$497.00M	$390.00M	$539.00M	$1.88B	$350.00M
Net income	$6.52B	$13.40B	$5.72B	$6.93B	$7.07B	$4.50B	$3.69B	$2.37B	$477.00M	$1.40B
EPS, basic	$3.73	$7.67	$3.28	$3.94	$3.97	$2.52	$2.07	$1.34	$0.27	$0.94
EPS, diluted	$3.72	$7.64	$3.26	$3.91	$3.94	$2.50	$2.06	$1.33	$0.27	$0.94
Diluted shares	1.75B	1.75B	1.75B	1.76B	1.79B	1.79B	1.78B	1.77B	1.75B	1.48B

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$8.52B	$7.62B	$6.90B	$9.88B	$9.80B	$6.84B	$3.86B	$3.84B	$9.41B	$18.62B
Short-term investments	$417.00M	$351.00M	$383.00M	$288.00M	$450.00M	$310.00M	$280.00M	$242.00M	$203.00M	$155.00M
Receivables	$7.93B	$6.92B	$6.57B	$6.22B	$6.49B	$6.41B	$5.42B	$5.18B	$5.25B	$3.25B
Inventory	$6.49B	$6.19B	$6.57B	$6.17B	$5.16B	$5.01B	$4.32B	$3.80B	$3.60B	$2.43B
Current assets	$26.00B	$23.66B	$22.67B	$25.22B	$24.24B	$20.44B	$15.67B	$14.63B	$20.15B	$26.78B
Goodwill	$24.04B	$23.11B	$23.68B	$22.80B	$23.23B	$23.74B	$23.20B	$23.25B	$24.02B	$7.68B
Total assets	$86.71B	$81.41B	$73.21B	$74.44B	$75.20B	$72.55B	$67.89B	$67.17B	$76.25B	$52.67B
Current liabilities	$16.50B	$14.16B	$13.84B	$15.49B	$13.11B	$11.91B	$10.86B	$9.01B	$8.91B	$6.66B
Short-term debt	$3.03B	$1.50B	$1.08B	$2.25B	$0	$7.00M	$1.28B	$7.00M	$508.00M	$3.00M
Long-term debt	$9.90B	$12.63B	$13.60B	$14.52B	$17.30B	$18.53B	$16.66B	$19.36B	$27.21B	$20.68B
Total debt	$12.93B	$14.13B	$14.68B	$16.77B	$17.30B	$18.53B	$17.94B	$19.37B	$27.72B	$20.68B
Total liabilities	$33.94B	$33.51B	$34.39B	$37.53B	$39.17B	$39.55B	$36.59B	$36.45B	$45.15B	$31.95B
Shareholders' equity	$52.13B	$47.66B	$38.60B	$36.69B	$35.80B	$32.78B	$31.09B	$30.52B	$30.90B	$20.54B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$9.57B	$8.56B	$7.26B	$9.58B	$10.53B	$7.90B	$6.14B	$6.30B	$5.57B	$3.20B
Capital expenditures	$2.17B	$2.21B	$2.20B	$1.78B	$1.89B	$2.18B	$1.64B	$1.39B	$1.14B	$1.12B
Free cash flow	$7.39B	$6.35B	$5.06B	$7.80B	$8.65B	$5.72B	$4.50B	$4.91B	$4.43B	$2.08B
Investing cash flow	-$2.42B	-$2.34B	-$3.13B	-$1.74B	-$2.01B	-$2.21B	-$1.81B	-$1.36B	-$9.62B	-$248.00M
Financing cash flow	-$6.31B	-$5.40B	-$7.09B	-$7.64B	-$5.49B	-$2.78B	-$4.29B	-$10.39B	-$5.28B	$11.15B
Dividends paid	$4.12B	$3.84B	$3.56B	$3.31B	$3.20B	$2.56B	$2.27B	$1.97B	$1.85B	$1.54B
Share repurchases	$893.00M	$1.29B	$1.23B	$3.79B	$2.30B	$403.00M	$718.00M	$238.00M	$117.00M	$522.00M
Stock-based compensation	$664.00M	$673.00M	$644.00M	$685.00M	$640.00M	$546.00M	$519.00M	$477.00M	$406.00M	$310.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	5.7%	4.6%	-8.1%	1.3%	24.5%	8.5%	4.3%	11.6%	31.3%	2.2%
Net income growth, YoY	-51.3%	134.2%	-17.5%	-2.0%	57.3%	21.9%	55.7%	396.4%	-65.9%	-68.3%
EPS growth, YoY	-51.3%	134.4%	-16.6%	-0.8%	57.6%	21.4%	54.9%	392.6%	-71.3%	-67.8%
Gross margin	56.4%	55.4%	55.2%	56.1%	57.0%	56.6%	58.5%	58.4%	54.7%	56.4%
Operating margin	18.2%	16.3%	16.2%	19.2%	19.6%	15.5%	14.2%	11.9%	5.7%	14.5%
Net margin	14.7%	31.9%	14.3%	15.9%	16.4%	13.0%	11.6%	7.7%	1.7%	6.7%
Free cash flow margin	16.7%	15.1%	12.6%	17.9%	20.1%	16.5%	14.1%	16.0%	16.2%	10.0%
Return on equity	12.5%	28.1%	14.8%	18.9%	19.8%	13.7%	11.9%	7.8%	1.5%	6.8%
Return on assets	7.5%	16.5%	7.8%	9.3%	9.4%	6.2%	5.4%	3.5%	0.6%	2.7%
Current ratio	1.58	1.67	1.64	1.63	1.85	1.72	1.44	1.62	2.26	4.02
Debt to equity	0.25	0.30	0.38	0.46	0.48	0.57	0.58	0.63	0.90	1.01

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$13.01B	$12.59B	$11.16B	$11.46B	$11.37B	$11.14B	$10.36B	$10.97B	$10.63B	$10.38B	$9.96B	$10.24B
Cost of revenue	$5.63B	$5.33B	$4.89B	$4.92B	$5.08B	$4.85B	$4.47B	$4.94B	$4.70B	$4.60B	$4.46B	$4.56B
Gross profit	$7.38B	$7.27B	$6.27B	$6.54B	$6.29B	$6.29B	$5.89B	$6.03B	$5.94B	$5.77B	$5.50B	$5.68B
Research and development	$920.00M	$892.00M	$767.00M	$735.00M	$766.00M	$725.00M	$716.00M	$749.00M	$713.00M	$698.00M	$684.00M	$700.00M
Selling, general and admin	$4.27B	$4.03B	$3.74B	$3.13B	$3.05B	$3.09B	$3.06B	$2.91B	$2.90B	$2.94B	$2.96B	$2.72B
Operating income	$1.36B	$1.69B	$1.34B	$2.25B	$2.06B	$2.05B	$1.69B	$1.91B	$1.86B	$1.67B	$1.39B	$1.78B
Interest expense	$350.00M	$351.00M	$174.00M	$120.00M	$121.00M	$121.00M	$131.00M	$136.00M	$142.00M	$140.00M	$141.00M	$159.00M
Pre-tax income	$1.23B	$1.52B	$1.45B	$2.36B	$2.18B	$2.15B	$1.78B	$2.03B	$1.94B	$1.61B	$1.44B	$1.79B
Income tax	$311.00M	$596.00M	$372.00M	$582.00M	$536.00M	$371.00M	$453.00M	-$7.20B	$294.00M	$305.00M	$211.00M	$201.00M
Net income	$920.00M	$928.00M	$1.08B	$1.78B	$1.64B	$1.78B	$1.32B	$9.23B	$1.65B	$1.30B	$1.23B	$1.59B
EPS, basic	$0.53	$0.53	$0.62	$1.01	$0.94	$1.02	$0.76	$5.29	$0.94	$0.74	$0.70	$0.92
EPS, diluted	$0.53	$0.53	$0.61	$1.01	$0.94	$1.01	$0.76	$5.26	$0.94	$0.74	$0.70	$0.91
Diluted shares	1.74B	1.74B	1.75B	-	1.75B	1.75B	1.75B	-	1.75B	1.75B	1.75B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$4.05B	$5.10B	$6.80B	$8.52B	$7.51B	$6.95B	$6.53B	$7.62B	$7.56B	$6.99B	$6.28B	$6.90B
Short-term investments	$246.00M	$499.00M	$492.00M	$417.00M	$222.00M	$331.00M	$312.00M	$351.00M	$230.00M	$232.00M	$367.00M	$383.00M
Receivables	$9.03B	$8.60B	$8.21B	$7.93B	$8.14B	$7.97B	$7.33B	$6.92B	$7.05B	$6.85B	$6.61B	$6.57B
Inventory	$7.34B	$7.32B	$6.99B	$6.49B	$6.71B	$6.95B	$6.64B	$6.19B	$6.81B	$6.81B	$6.83B	$6.57B
Current assets	$23.50B	$24.52B	$25.51B	$26.00B	$24.84B	$24.47B	$23.15B	$23.66B	$23.80B	$23.12B	$22.38B	$22.67B
Goodwill	$32.64B	$35.24B	$35.22B	$24.04B	$23.97B	$23.95B	$23.36B	$23.11B	$23.66B	$23.31B	$23.38B	$23.68B
Total assets	$108.25B	$109.22B	$110.43B	$86.71B	$84.18B	$84.00B	$81.45B	$81.41B	$74.36B	$73.02B	$72.47B	$73.21B
Current liabilities	$16.15B	$17.81B	$18.38B	$16.50B	$14.58B	$13.44B	$13.00B	$14.16B	$14.90B	$13.76B	$14.02B	$13.84B
Short-term debt	$1.71B	$3.00B	$4.41B	$3.03B	$1.34B	$507.00M	$506.00M	$1.50B	$2.15B	$1.61B	$2.01B	$1.08B
Long-term debt	$29.45B	$29.60B	$29.64B	$9.90B	$11.60B	$12.93B	$12.74B	$12.63B	$12.82B	$13.14B	$12.58B	$13.60B
Total debt	$31.16B	$32.61B	$34.05B	$12.93B	$12.94B	$13.44B	$13.24B	$14.13B	$14.98B	$14.75B	$14.59B	$14.68B
Total liabilities	$56.62B	$57.45B	$57.73B	$33.94B	$32.92B	$33.17B	$32.38B	$33.51B	$34.33B	$33.46B	$33.42B	$34.39B
Shareholders' equity	$51.03B	$51.11B	$52.06B	$52.13B	$50.95B	$50.56B	$48.81B	$47.66B	$39.80B	$39.32B	$38.81B	$38.60B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$1.74B	$2.49B	$1.31B	$3.31B	$2.79B	$2.05B	$1.42B	$2.87B	$2.71B	$1.96B	$1.02B	$3.04B
Capital expenditures	$513.00M	$497.00M	$399.00M	$689.00M	$496.00M	$502.00M	$484.00M	$720.00M	$556.00M	$533.00M	$398.00M	$755.00M
Free cash flow	$1.22B	$1.99B	$916.00M	$2.63B	$2.29B	$1.54B	$933.00M	$2.15B	$2.15B	$1.43B	$627.00M	$2.28B
Investing cash flow	-$385.00M	-$673.00M	-$20.32B	-$913.00M	-$457.00M	-$582.00M	-$470.00M	-$866.00M	-$594.00M	-$453.00M	-$425.00M	-$824.00M
Financing cash flow	-$2.40B	-$3.52B	$17.31B	-$1.40B	-$1.76B	-$1.10B	-$2.06B	-$1.86B	-$1.58B	-$791.00M	-$1.18B	-$2.05B
Dividends paid	$1.09B	$1.10B	$1.10B	$1.03B	$1.03B	$1.03B	$1.03B	$958.00M	$960.00M	$961.00M	$957.00M	$888.00M
Share repurchases	$11.00M	$1.04B	$180.00M	$302.00M	$305.00M	$6.00M	$280.00M	$315.00M	$751.00M	$3.00M	$226.00M	$259.00M
Stock-based compensation	$137.00M	$168.00M	$317.00M	$113.00M	$120.00M	$142.00M	$289.00M	$111.00M	$117.00M	$141.00M	$304.00M	$114.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	14.5%	13.0%	7.8%	4.4%	6.9%	7.4%	4.0%	7.2%	4.9%	4.0%	2.2%	1.5%
Net income growth, YoY	-44.0%	-47.8%	-18.7%	-80.8%	-0.1%	36.6%	8.2%	479.0%	14.6%	-5.3%	-7.1%	54.3%
EPS growth, YoY	-43.6%	-47.5%	-19.7%	-80.8%	0.0%	36.5%	8.6%	478.0%	14.6%	-5.1%	-6.7%	54.2%
Gross margin	56.8%	57.7%	56.2%	57.0%	55.4%	56.4%	56.9%	55.0%	55.8%	55.6%	55.2%	55.5%
Operating margin	10.4%	13.4%	12.0%	19.6%	18.1%	18.4%	16.3%	17.4%	17.5%	16.1%	13.9%	17.4%
Net margin	7.1%	7.4%	9.6%	15.5%	14.5%	16.0%	12.8%	84.1%	15.5%	12.5%	12.3%	15.6%
Free cash flow margin	9.4%	15.8%	8.2%	22.9%	20.2%	13.9%	9.0%	19.6%	20.2%	13.8%	6.3%	22.3%
Current ratio	1.45	1.38	1.39	1.58	1.70	1.82	1.78	1.67	1.60	1.68	1.60	1.64
Debt to equity	0.61	0.64	0.65	0.25	0.25	0.27	0.27	0.30	0.38	0.38	0.38	0.38

Source: XBRL data Abbott Laboratories files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ABT peers

Company	Revenue	Growth	Net income	Net margin	Market cap
ABT	$48.23B	+10.0%	$4.70B	9.7%	$190.39B
LLYEli Lilly and Company	$86.46B	+45.5%	$27.58B	31.9%	$1.27T
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
ABBVAbbVie Inc.	$66.01B	+10.7%	$10.34B	15.7%	$514.92B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$361.71B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$289.10B
NVONovo Nordisk A/S	DKK 309.06B	+6.4%	DKK 102.43B	33.1%	$178.51B
PFEPfizer Inc.	$63.63B	+1.3%	$4.03B	6.3%	$167.49B

ABT FAQ

9 questions

What is ABT revenue?
Abbott Laboratories (ABT) reported $48.23B of revenue for the twelve months ended Sep 30, 2026. That is up 10.0% from the year before. Revenue for fiscal 2025 was $44.33B.
Is ABT profitable?
Yes. Abbott Laboratories earned $4.70B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.7%.
How much cash and debt does ABT have?
Abbott Laboratories reported $4.05B in cash and cash equivalents and $31.16B of debt on its most recent balance sheet in SEC filings.
How fast is ABT revenue growing?
Abbott Laboratories's revenue changed +5.7% in fiscal 2025, to $44.33B. Its compound annual growth rate was +5.1% over 5 years and +8.1% over 10 years.
What is ABT gross margin?
Abbott Laboratories's gross profit was $27.46B on $48.23B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 56.9%.
What is ABT free cash flow?
Abbott Laboratories generated $6.76B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $8.86B less capital expenditures.
What is ABT earnings per share?
Diluted earnings per share were $2.68 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did ABT last report financial results?
The latest statements here come from Abbott Laboratories's 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
Where does this ABT financial data come from?
Quantisnow builds these statements from the structured XBRL data Abbott Laboratories files with the SEC. It is provided for information only and is not investment advice.